利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.026 秒)

    Useful mutations of bacterial alkaline protease
    4.
    发明授权
    Useful mutations of bacterial alkaline protease 失效
    细菌碱性蛋白酶有用的突变

    公开(公告)号：US06506589B1

    公开(公告)日：2003-01-14

    申请号：US08486846

    申请日：1995-06-07

    申请人： Sven Hastrup ,  Sven Branner ,  Fanny Norris ,  Steffen Bjørn Petersen ,  Leif Nørskov-Lauridsen ,  Villy Johannes Jensen ,  Dorrit Aaslyng

    发明人： Sven Hastrup ,  Sven Branner ,  Fanny Norris ,  Steffen Bjørn Petersen ,  Leif Nørskov-Lauridsen ,  Villy Johannes Jensen ,  Dorrit Aaslyng

    IPC分类号： C12N956

    CPC分类号： C11D3/386 ,  C12N9/54

    摘要： The present invention relates to mutations of the subtilisin gene, some of which result in changes in the chemical characteristics of subtilisin enzyme. Mutations are created at specific nucleic acids of the subtilisin gene and, in various specific embodiments, the mutant enzymes possess altered chemical properties including, but not limited to, increased stability to oxidation, augmented proteolytic activity, and improved washability. The present invention also relates, but is not limited to, the amino acid and DNA sequences for two proteases derived from Bacillus lentus variants, subtilisin 147 and subtilisin 309, as well as mutations of these genes and the corresponding mutant enzymes.

    摘要翻译： 本发明涉及枯草杆菌蛋白酶基因的突变，其中一些导致枯草杆菌蛋白酶的化学特性的变化。 在枯草杆菌蛋白酶基因的特定核酸上产生突变，并且在各种具体实施方案中，突变酶具有改变的化学性质，包括但不限于氧化增强的稳定性，增强的蛋白水解活性和改善的可洗性。 本发明还涉及但不限于来自迟缓芽孢杆菌变体，枯草杆菌蛋白酶147和枯草杆菌蛋白酶309的两种蛋白酶的氨基酸和DNA序列，以及这些基因和相应的突变酶的突变。

    Human Spasmolytic Polypeptide in Glycosylated Form
    7.
    发明申请
    Human Spasmolytic Polypeptide in Glycosylated Form 审中-公开
    人解脂多糖在糖基化形式

    公开(公告)号：US20090011461A1

    公开(公告)日：2009-01-08

    申请号：US12040141

    申请日：2008-02-29

    申请人： Lars Thim ,  Kjeld Norris ,  Fanny Norris ,  Soren Erik Bjorn ,  Mogens Christensen ,  Per Franklin Nielsen

    发明人： Lars Thim ,  Kjeld Norris ,  Fanny Norris ,  Soren Erik Bjorn ,  Mogens Christensen ,  Per Franklin Nielsen

    IPC分类号： C12P21/04

    CPC分类号： C07K14/575 ,  A61K38/00

    摘要： Human spasmolytic polypeptide (HSP) which has the amino acid sequence Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyror a functionally equivalent homologue thereof, characterized by being in glycosylated form.

    摘要翻译： 具有氨基酸序列的人解痉多肽（HSP）Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyr或其功能等同同系物，其特征在于呈糖基化形式。

    Human Kunitz-type protease inhibitor variants
    8.
    发明授权
    Human Kunitz-type protease inhibitor variants 失效
    人类Kunitz型蛋白酶抑制剂变体

    公开(公告)号：US5629176A

    公开(公告)日：1997-05-13

    申请号：US334773

    申请日：1994-11-04

    申请人： S.o slashed.ren E. Bj.o slashed.rn ,  Kjeld Norris ,  Fanny Norris ,  Lars C. Petersen ,  Ole H. Olsen

    发明人： S.o slashed.ren E. Bj.o slashed.rn ,  Kjeld Norris ,  Fanny Norris ,  Lars C. Petersen ,  Ole H. Olsen

    IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K38/55 ,  A61P7/02 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  C07H21/04 ,  C07K14/47 ,  C07K14/81 ,  C12N1/19 ,  C12N15/15 ,  C12P21/02 ,  C12R1/865 ,  C12P21/06 ,  C07K1/00 ,  C12N1/20

    CPC分类号： C07K14/8114 ,  A61K38/00

    摘要： A variant of the C-terminal Kunitz-type protease inhibitor domain of the .alpha.3 chain of human type VI collagen, the variant comprising the following amino acid sequence X.sup.1 X.sup.16 Asp Ile Cys Lys Leu Pro Lys Asp X.sup.2 Gly X.sup.3 Cys X.sup.4 X.sup.5 X.sup.6 X.sup.7 X.sup.8 X.sup.9 Trp Tyr Tyr Asp Pro Asn Thr Lys Ser Cys Ala Arg Phe X.sup.10 Tyr Gly Gly Cys X.sup.11 X.sup.12 X.sup.13 Glu Asn Lys Phe X.sup.14 Ser Gln Lys Glu Cys Glu Lys Val Cys Ala Pro X.sup.15 (SEQ ID NO. 1) wherein X.sup.1, X.sup.15, and X.sup.16 represents a naturally occurring amino acid residues except Cys and X.sup.2 -X.sup.14 each independently respresents a naturally occurring amino acid residue, with the proviso that at least one of the amino acid residues X.sup.1 -X.sup.16 is different from the corresponding amino acid residue of the native sequence. Alternatively, the N-terminal Asp may be preceded by H or 3-5 amino acid residues and the C-terminal Pro may be followed by OH or 3-5 amino acid residues.

    摘要翻译： 人类VI型胶原α3链的C末端Kunitz型蛋白酶抑制剂结构域的变体，该变体包含以下氨基酸序列X1 X16 Asp Ile Cys Lys Leu Pro Lys Asp X2 Gly X3 Cys X4 X5 X6 X7 X8 X9 Trp Tyr Tyr Asp Pro Asn Thr Lys Ser Cys Ala Arg Phe X10 Tyr Gly Gly Cys X11 X12 X13 Glu Asn Lys Phe X14 Ser Gln Lys Glu Cys Glu Lys Val Cys Ala Pro X15（SEQ ID NO.1）其中X1， X15和X16表示天然存在的氨基酸残基，除了Cys和X2-X14各自独立地表示天然存在的氨基酸残基，条件是至少一个氨基酸残基X1-X16不同于相应的氨基酸残基 的天然序列。 或者，N-末端Asp可以在H或3-5​​个氨基酸残基之前，C末端Pro可以之后是OH或3-5​​个氨基酸残基。